ICU vs SRZN

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 09, 2026

ICU

49.1
AI Score
VS
ICU Wins

SRZN

30.0
AI Score

Investment Advisor Scores

ICU

49score
Recommendation
HOLD

SRZN

30score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric ICU SRZN Winner
Revenue 1.11M 10.00M SRZN
Net Income -7.25M -77.33M ICU
Net Margin -653.2% -773.3% ICU
Operating Income -7.39M -20.83M ICU
ROE -168.8% 35.4% SRZN
ROA -83.8% -66.9% SRZN
Total Assets 8.65M 115.61M SRZN
Cash 6.96M 102.04M SRZN
Current Ratio 1.89 12.14 SRZN

Relative Price Performance (Last 90 Days)

ICU 1M: -65.1% · 3M: -67.0% SRZN 1M: +33.3% · 3M: +32.2%

Current Technical Phase

ICU

Markdown
Sell / avoid

Price below a falling SMA50 (slope -11.0%), weak momentum, RSI 23

RSI (14): 22.7 · Price: $1.05

SRZN

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (8.5% over 20 days), RSI 60

RSI (14): 59.8 · Price: $31.67

Fundamentals Snapshot

Metric ICU SRZN
Market Cap — —
Forward P/E -0.5 -6.7
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.8% 4.1%
Gross Margin 0.9% -2.6%
Operating Margin -8.2% -4.9%
EPS -2.97 -41.94
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, ICU is currently the stronger investment candidate, winning 3 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.